Furrer M, Schneider K, Gallino A, Schneider J, Vogt P, Turina M
Helv Chir Acta. 1989 Jan;55(5):629-32.
Heart transplantation (HTPL) has worldwide become a well established therapy of terminal heart failure. Besides non-invasive parameters the endomyocardial biopsy (EMB) is proved to be the goldstandard method for early detection of graft rejection. At the University Hospital of Zurich 31 HTPL have been performed between September 1985 and December 1987. 100 out of 460 EMB's showed moderate or severe rejection and needed additional immunosuppressive treatment. 1.5% of all EMB's caused further treatment due to local or systemic complications.
心脏移植在全球已成为终末期心力衰竭的一种成熟疗法。除了非侵入性参数外，心内膜活检被证明是早期检测移植物排斥反应的金标准方法。在苏黎世大学医院，1985年9月至1987年12月期间进行了31例心脏移植手术。460次心内膜活检中有100次显示中度或重度排斥反应，需要额外的免疫抑制治疗。所有心内膜活检中有1.5%因局部或全身并发症而需要进一步治疗。
